Physician profile
Kathleen L Todd
NPI 1013983865
$60,488.16
in general payments reported to CMS, 2019-2025
43 companies · $56.67 in 2025
The $56.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $19K · 2021: $5,202 · 2022: $26.62 · 2023: $120 · 2024: $16.33 · 2025: $56.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $51,188.88 | 2019-2020 | |
| Allergan, INC. | $3,926.15 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $1,238.15 | 2021 | |
| Abbvie INC. | $961.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $419.54 | 2019-2021 | |
| Lilly USA, LLC | $328.85 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $266.53 | 2019-2021 | |
| Novo Nordisk INC | $196.77 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $178.23 | 2019-2020 | |
| Orexo US, INC. | $176.70 | 2019-2021 | |
| Indivior INC. | $150.35 | 2019-2021 | |
| Amgen INC. | $147.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.63 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.00 | 2019-2021 | |
| Amarin Pharma, INC. | $103.15 | 2020-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.